Tirzepatide
Also called Mounjaro, Zepbound.
By Dr Chad Okay4 min read
Tirzepatide is a synthetic peptide that activates two gut-hormone receptors at once: GLP-1 and GIP. It is made by Eli Lilly and sold in the UK as Mounjaro for both type 2 diabetes and weight management. The dual mechanism produces stronger weight-loss results than semaglutide in clinical trials, with side effects of similar character.
What makes it different
Most GLP-1 drugs target just the GLP-1 receptor. Tirzepatide is the first approved drug to target both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone, also released by the gut after eating. The combination produces stronger insulin release and more weight loss than either signal alone, at least in current trials. Drugs that target three receptors at once (like retatrutide, in late-stage trials) are next.
How weight loss compares to semaglutide
In the SURMOUNT-1 trial of tirzepatide for obesity, participants on the highest dose (15 mg weekly) lost an average of 20.9% of body weight over 72 weeks (the efficacy estimand, for people who stayed on the drug, was 22.5%). The same trial design with semaglutide (STEP-1) showed 14.9%. In the first head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide. Real-world results vary, and the SURPASS trials in diabetes showed slightly smaller differences. NICE approved tirzepatide for obesity in the UK in 2024 (TA1026), with eligibility limited to a body mass index (BMI) of 35 or above with weight-related conditions, plus structured behavioural support.
Doses and titration
- Starting dose: 2.5 mg once weekly, for 4 weeks.
- Step 2: 5 mg weekly. Many people stay here.
- Higher doses: 7.5 mg, 10 mg, 12.5 mg, 15 mg. Titrated up at 4-week intervals if tolerated and required.
- Each dose step typically triggers a 1 to 2 week recurrence of side effects before the gut adapts.
Side effects
The side-effect profile is similar to semaglutide. Nausea is the most common, peaking around the high 20s percent at the higher doses (Zepbound label: about 25% / 29% / 28% across 5/10/15 mg). Constipation does NOT rise linearly with dose, the Zepbound label reports about 17% on 5 mg, 14% on 10 mg, and 11% on 15 mg. Sulphur burps are reported more often by tirzepatide users than semaglutide users in real-world reporting. Most symptoms peak in weeks 2 to 4 of each dose escalation and ease as the gut adapts.
How it is taken in the UK
Mounjaro is prescription-only. It is available privately through online and high-street pharmacies, and via the NHS for diabetes. NHS access for obesity is being phased in from 2025, starting with people with BMI 40 or above with four weight-related comorbidities. Private prices in the UK ranged from around £120 to £340 per month in 2026, depending on dose and pharmacy.
If something feels wrong
This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.
Common questions
On weight loss, yes. In the first head-to-head trial (SURMOUNT-5), tirzepatide produced 20.2% average weight loss compared with 13.7% for semaglutide. Side effects are similar in frequency and character.
Sources
- 1Tirzepatide for managing overweight and obesity (TA1026), RecommendationsNICE
- 2SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al, NEJM 2022)PubMed
- 3Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
- 4STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al, NEJM 2021)PubMed
- 5SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne et al, 2025 (-20.2% vs -13.7% at 72 weeks)NEJM (PubMed)
- 6ZEPBOUND (tirzepatide) US Prescribing Information, adverse reactions by doseDailyMed / Eli Lilly
- 7SURMOUNT-4: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (JAMA 2023)PubMed
- 8NHS England, Interim commissioning guidance: NICE TA1026 tirzepatideNHS England
- 9Clinical perspectives on the GIP/GLP-1 receptor agonist tirzepatide (mechanism review, 2022)Frontiers in Endocrinology / PMC
Related terms



